Does Serum LH Level Influence IVF Outcomes in Women with PCOS Undergoing GnRH-Antagonist Stimulation: A Novel Indicator

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Aug 26

PMID 36012922

Authors

Jing Wang

Jinli Ding

Bing Qu

Yi Zhang

Qi Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the influence of LH levels on the IVF/ICSI outcomes in women with PCOSundergoing GnRH-antagonist stimulation protocol.

Methods: A total of 142 IVF/ICSI patients in which the females were diagnosed with PCOS and underwent GnRH-antagonist protocol for ovarian stimulation were enrolled. Patients were divided into three groups based on basal LH (bLH) level, LH level on trigger day (hLH), and the ratio of hLH/bLH. The LH levels detected on different days in the stimulation cycle as well as their relationships with the IVF/ICSI outcomes were investigated. The main outcomes we observed were the number of oocytes retrieved, the cumulative chemical pregnancy rate, clinical pregnancy rate, and live birth rate. Other factors included the number of normally fertilized oocytes (2PN), top-quality embryo rate, and total Gn dose.

Results: There was no significant difference in the included outcomes and baseline characteristics among different groups based on bLH levels. When patients were grouped according to hLH levels (≤2 mIU/mL, 2-5 mIU/mL and ≥5 mIU/mL), we found decreased levels of basal FSH and LH in the group of hLH ≤ 2 mIU/mL than the other two groups. Then the ratio of hLH/bLH was calculated for each patient. Patients with hLH/bLH ≥ 1 had a higher top-quality embryo rate than those with hLH/bLH between 0.5 and 1.0. Nevertheless, the cumulative clinical pregnancy rate was significantly higher in the hLH/bLH ≤ 0.5 group than in the other two groups.

Conclusions: The study proposed the hLH/bLH ratio as a potential in predicting the influence of LH level on the embryo development potential as well as pregnancy outcomes in women with PCOS undergoing GnRH-antagonist stimulation cycles.

Citing Articles

Basal serum luteinizing hormone, total testosterone, and free testosterone levels do not impact IVF outcomes in patients with polycystic ovary syndrome.

Kugelman N, Digby A, Rotshenker-Olshinka K, Bellemare V, Pooni A, Son W J Turk Ger Gynecol Assoc. 2024; 25(4):192-199.

PMID: 39658861 PMC: 11632639. DOI: 10.4274/jtgga.galenos.2024.2024-2-9.

Reproductive outcomes in fresh transfer cycles and antagonists with premature luteinizing and/or progesterone surge: a single center retrospective cohort study.

Wei C, Zhang J, Xiang S, Lian F Front Endocrinol (Lausanne). 2024; 15:1411106.

PMID: 39381441 PMC: 11458468. DOI: 10.3389/fendo.2024.1411106.

Effect of LH level on HCG trigger day on clinical outcomes in patients with diminished ovarian reserve undergoing GnRH-antagonist protocol.

Zhang Q, Zhang K, Gao Y, He S, Meng Y, Ming L Reprod Biol Endocrinol. 2024; 22(1):107.

PMID: 39175038 PMC: 11340131. DOI: 10.1186/s12958-024-01280-0.

Impact of stimulation with luteinizing hormone activity on IVF outcomes in patients with polycystic ovary syndrome.

Kugelman N, Pooni A, Rotshenker-Olshinka K, Bellemare V, Digby A, Dahan M J Turk Ger Gynecol Assoc. 2024; 25(2):60-65.

PMID: 38867686 PMC: 11576635. DOI: 10.4274/jtgga.galenos.2024.2023-12-9.

Ovarian response determines the luteinizing hormone suppression threshold for patients following the gonadotrophin releasing hormone antagonist protocol: A retrospective cohort study.

Li Q, Zhou X, Ye B, Tang M, Zhu Y Heliyon. 2024; 10(1):e23933.

PMID: 38187350 PMC: 10767281. DOI: 10.1016/j.heliyon.2023.e23933.

References

Valdimarsdottir R, Wikstrom A, Kallak T, Elenis E, Axelsson O, Preissl H . Pregnancy outcome in women with polycystic ovary syndrome in relation to second-trimester testosterone levels. Reprod Biomed Online. 2020; 42(1):217-225. DOI: 10.1016/j.rbmo.2020.09.019. View

Stadtmauer L, Sarhan A, Duran E, Beydoun H, Bocca S, Pultz B . The impact of a gonadotropin-releasing hormone antagonist on gonadotropin ovulation induction cycles in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril. 2010; 95(1):216-20. DOI: 10.1016/j.fertnstert.2010.05.023. View

Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani P . Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod. 2005; 20(9):2421-5. DOI: 10.1093/humrep/dei074. View

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2003; 19(1):41-7. DOI: 10.1093/humrep/deh098. View

Kummer N, Weitzman V, Benadiva C, Schmidt D, Engmann L, Nulsen J . In vitro fertilization outcomes in patients experiencing a premature rise in luteinizing hormone during a gonadotropin-releasing hormone antagonist cycle. Fertil Steril. 2011; 95(8):2592-4. DOI: 10.1016/j.fertnstert.2010.12.046. View

Roth L, Bradshaw-Pierce E, Allshouse A, Lesh J, Chosich J, Bradford A . Evidence of GnRH antagonist escape in obese women. J Clin Endocrinol Metab. 2014; 99(5):E871-5. PMC: 4010706. DOI: 10.1210/jc.2013-3598. View

Goodarzi M, Dumesic D, Chazenbalk G, Azziz R . Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011; 7(4):219-31. DOI: 10.1038/nrendo.2010.217. View

Ertunc D, Tok E, Savas A, Ozturk I, Dilek S . Gonadotropin-releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome. Fertil Steril. 2009; 93(4):1179-84. DOI: 10.1016/j.fertnstert.2008.11.030. View

Chaudhari N, Dawalbhakta M, Nampoothiri L . GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018; 16(1):37. PMC: 5896071. DOI: 10.1186/s12958-018-0354-x. View

10.

Griesinger G, Diedrich K, Tarlatzis B, Kolibianakis E . GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006; 13(5):628-38. DOI: 10.1016/s1472-6483(10)60652-9. View

11.

Cardone V . GnRH antagonists for treatment of polycystic ovarian syndrome. Fertil Steril. 2003; 80 Suppl 1:S25-31; discussion S32-4. DOI: 10.1016/s0015-0282(03)00763-5. View

12.

Cui N, Wang H, Wang W, Zhang J, Xu Y, Jiang L . Impact of Body Mass Index on Outcomes of In Vitro Fertilization/Intracytoplasmic Sperm Injection Among Polycystic Ovarian Syndrome Patients. Cell Physiol Biochem. 2016; 39(5):1723-1734. DOI: 10.1159/000447873. View

13.

Provost M, Acharya K, Acharya C, Yeh J, Steward R, Eaton J . Pregnancy outcomes decline with increasing body mass index: analysis of 239,127 fresh autologous in vitro fertilization cycles from the 2008-2010 Society for Assisted Reproductive Technology registry. Fertil Steril. 2015; 105(3):663-669. DOI: 10.1016/j.fertnstert.2015.11.008. View

14.

Yang W, Yang R, Lin M, Yang Y, Song X, Zhang J . Body mass index and basal androstenedione are independent risk factors for miscarriage in polycystic ovary syndrome. Reprod Biol Endocrinol. 2018; 16(1):119. PMC: 6245701. DOI: 10.1186/s12958-018-0438-7. View

15.

Dovey S, McIntyre K, Jacobson D, Catov J, Wakim A . Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles. Fertil Steril. 2011; 96(3):585-9. DOI: 10.1016/j.fertnstert.2011.06.042. View

16.

Escobar-Morreale H . Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018; 14(5):270-284. DOI: 10.1038/nrendo.2018.24. View

17.

Huang S, Huang H, Yu H, Wang H, Chen C, Lee C . Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer. Taiwan J Obstet Gynecol. 2012; 50(4):432-5. DOI: 10.1016/j.tjog.2011.10.006. View

18.

Katulski K, Podfigurna A, Czyzyk A, Meczekalski B, Genazzani A . Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine. 2018; 61(1):149-157. PMC: 5997113. DOI: 10.1007/s12020-018-1609-1. View

19.

. The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. Hum Reprod. 2011; 26(6):1270-83. DOI: 10.1093/humrep/der037. View

20.

Zhang D, Zhang D, Sun Z, Deng C, Yu Q, Zhen J . The effect of a transient premature luteinizing hormone surge without elevated serum progesterone on in vitro fertilization outcomes in a gonadotropin-releasing hormone antagonist flexible protocol. Gynecol Endocrinol. 2019; 36(6):550-553. DOI: 10.1080/09513590.2019.1683730. View